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Human serum aryl acylamidase associated with serum cholinesterase was purified to homogeneity. Evidence for 
the identity of the two enzymes was based on co-elution profiles, co-purification in the different steps including 
affinity chromatography with constant ratios of specific activity and percentage recoveries, co-migration on gel 
electrophoresis, parallel inhibition by typical cholinesterase inhibitors and co-precipitation by antibody raised 
against the purified enzyme. Human liver aryl acylamidase was partially purified. Based on the elution profiles, 
purification data, inhibitory characteristics and gel electrophoresis it was concluded that aryl acrylamidase of liver 
was not associated with liver cholinesterase. More conclusive evidence for the non-association of the liver aryl 
acylamidase and cholinesterase came from their clear-cut separation on procainamide-Sepharose affinity chroma- 
tography. Both the serum and liver aryl acylamidase were compared with the purified erythrocyte aryl acylamidase 
associated with acetylcholinesterase. While the erythrocyte and serum aryl acylamidases showed some similarities in 
their sensitivities to amines like serotonin or tryptamine and choline derivatives, the liver enzyme was unaffected by 
any of these compounds. A notable observation was the activation by tyramine of the serum aryl acylamidase but not 
the erythrocyte and liver aryl acylamidases. The liver aryl acylamidase also differed from the other two in its relative 
insensitivity to inhibition by eserine, neostygmine and other cholinesterase inhibitors. Immunodiffusion and 
immunoprecipitation studies showed that the aryl acylamidases from the liver and erythrocytes were immunologi- 
cally non-identical with the serum enzyme. 
The existence of acetylcholinesterases (true cholinesterases) 
and pseudocholinesterases (non-specific cholinesterases or 
cholinesterases) has been known for several years. Their 
distinction has been mainly based on their substrate specifi- 
cities and inhibitor sensitivities [I - 41. Acetylcholine and 
acetyl-D-methylcholine are preferred substrates of acetylcholin- 
esterase [I] and the compound bis(4-allyldimethylammonium- 
phenyl)pentan-3-one dibromide (BW284C51) is a selective 
inhibitor of acetylcholinesterase [5]. Similarly butyrylcholine 
and benzoylcholine are considered to be preferred substrates of 
pseudocholinesterase and the compounds tetraisopropylpyro- 
phosphoramide and ethopropazine are selective inhibitors of 
pseudocholinesterase [I ,  5,6]. These two classes of cholines- 
terase also differ in their occurrence. Caudate nucleus of brain, 
erythrocyte membrane and electric eel are known sources of 
acetylcholinesterase and serum is a well known source of 
pseudocholinesterase [7 - 91. The active site of both acetyl- 
cholinesterase and pseudocholinesterase is known to possess an 
esteratic and an anionic site [lo, 111 but acetylcholinesterase 
may possess additional anionic centers [Ill.  Koelle et al. 
[I2 - 141 suggested the possibility of pseudocholinesterase 
acting as a post-translational precursor of acetylcholinesterase 
in the cat superior cervical ganglion. However in the rat 
superior cervical ganglion this could not be confirmed [5, 151. 
Evidence from this laboratory and from other workers 
[I 6 - 191 suggest that an aryl acylamidase activity specifically 
Enzymes. Aryl acylamidase or aryl-acylamide amidohydrolase (EC 
3.5.1.13); acetylcholinesterase or acetylcholine acetylhydrolase or true 
cholinesterase (EC 3.1 .I .7); cholinesterase or acylcholine acylhydrolase or 
pseudocholinesterase (EC 3.1.1.8). 
Trivial Name. BW284C51, bis(4-a1lyldimethylammoniumphenyl)- 
pentan-3-one dibromide. 
sensitive to serotonin is associated with acetylcholinesterase of 
different sources such as electric eel, brain and erythrocytes. An 
aryl acylamidase of liver which is insensitive to serotonin is also 
known [20, 211. It was therefore of interest to know whether 
aryl acylamidases in general are associated with cholinesterases 
of different sources and whether any differences in the amine 
sensitivities of the aryl acylamidases exist. Such a study may 
lead to methods of differentiating the cholinesterases on the 
basis of the amine sensitivities of the aryl acylamidase with 
which they are associated. In the present work we have purified 
the aryl acylamidase of human serum and shown that it is 
associated with the serum cholinesterase. We have also com- 
pared the properties and amine sensitivity of the human serum 
aryl acylamidase with the human erythrocyte aryl acylamidase 
associated with acetylcholinesterase and with the human liver 
aryl acylamidase. 
MATERIALS AND METHODS 
Materials 
Procainamide was obtained from Sarabhai M. Chemicals 
(India), and anti-(rabbit IgG) was from Miles Laboratories, 
USA. All other chemicals were from Sigma Chemicals Co., 
USA or from sources mentioned earlier [IX, 291. 
Human erythrocytes and plasma were obtained from the 
blood bank of the hospital. 
Purification of Serum Aryl Acylamidase 
Step. 1. Preparation of Serum. 200 ml of citrated human 
plasma irrespective ofblood groups stored at 4 "C for 5 - 7 days 
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was used as the starting material. The plasma was clotted by the 
addition of CaCl, to a final concentration of 2mM.  After 
keeping for 5 h at 4 ' C the fibrin clot was removed by allowing 
the serum to filter through a nylon cloth. 
Step 2. DEAE-cellulose Chromatography. DEAE-cellulose 
(Whatman DE 32) was packed in a column (3.5 cm x 40 cm) 
and equilibrated with 20 mM sodium acetate buffer pH 4.1 
containing 1 mM EDTA and 1 mM 2-mercaptoethanol. The 
serum after dialysis against 12 1 of equilibrating buffer was 
centrifuged to remove the precipitated proteins. The clear 
serum was applied on the DEAE-cellulose column and washed 
with 6 1 of the equilibrating buffer. The enzyme was eluted by 
applying a 0-0.2 M NaCl gradient (total vol. 1.5 1) in the 
equilibrating buffer. The flow rate was maintained at  40 ml/h 
and fractions of 25 ml were collected. The active fractions 
(fractions 26 - 36) were pooled. 
Step 3. Concanavalin-A - Sepharose Chromatography. Con- 
canavalin A was coupled to Sepharose 4 B  according to the 
method of Cuatrecasas [22, 231. The gel (containing 7 mg 
concanavalin Ajml) was packed in a column (2.7 cm x 6.5 cm) 
and equilibrated with 20 mM sodium acetate buffer pH 5.0. 
The pooled fractions from DEAE-cellulose were dialysed 
against 12 1 of the same buffer and applied on the concanavalin- 
A-Sepharose column. After washing with 0.5 M NaCl in 
20 mM acetate buffer pH 5.0, the enzyme was eluted at 25 "C 
with 0.05 M methyl a-glucoside in the wash buffer. The flow 
rate was maintained at  20 ml/h and fractions of 10 ml were 
collected. The active fractions (fractions 1 - 7) were pooled. 
Step 4 .  Procainamide-Sepharose Aj,,nity Chromatography. 
The method was essentially the same as that used by Lockridge 
and La Du [24] for the purification of serum cholinesterase. 
However the length of the spacer arm was increased from six to 
ten carbon atoms to enhance the efficiency of binding of the 
enzyme to the ligand. The preparation of the affinity media was 
done according to the method of Cuatrecasas [22, 231. The 
spacer arm was synthesised by the successive addition of 
hexanediamine and succinic anhydride to cyanogen-bromide- 
activated. Sepharose 4B. Finally 10 pmol procainamide/ml 
gel was coupled to the carboxyl end of the spacer arm using 
l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 
[19]. The affinity gel was packed in a column (1.4 cm x 10 cm) 
and equilibrated with 20 mM potassium phosphate buffer 
pH 7.0. The pooled concanavalin-A - Sepharose eluate was 
dialysed against 2 1 of the equilibration buffer and applied on 
the column. The column was washed with 125 ml of 20 mM 
potassium phosphate buffer pH 7.0 containing 0.1 M NaCl. 
The enzyme was eluted by applying a linear gradient of 0.1 - 
0.6 M NaCl (total volume of 100 ml) in the equilibration buffer 
at  a flow rate of 15 ml/h. Fractions of 5 ml were collected. 
Active fractions were pooled and dialysed against 20mM 
potassium phosphate buffer pH 7.0. 
Purification of Human Erythrocyte Aryl Acylamidase 
The purification of human erythrocyte aryl acylamidase 
was done as described earlier [I91 using m-aminophenyl- 
trimethylammonium chloride-hydrochloride - Sepharose 4B 
affinity chromatography. 
Puri3cation of Human Liver Aryl Acylamidase 
Step 1. Extraction ofthe Enzyme. 10 g offrozen human liver 
of a 55-year-old male was minced and homogenized in 80 ml of 
20 mM potassium phosphate buffer p H  7.0 containing 0.5 % 
(v/v) Triton X-100 in a Waring blendor at maximum speed. The 
homogenate was centrifuged at 55000 x g for 1 h and the 
supernatant collected. 
Step 2. Ammonium Sulfate Precipitation. The supernatant 
was subjected to a 33 - 60 (NH4),S04 fractionation and the 
precipitated protein centrifuged down at 12000 x g for 30 min. 
The pellet was dissolved in 3 ml of 20 mM potassium phos- 
phate buffer pH 7.0 and dialysed against 1.5 1 of the same 
buffer. 
Stej' 3. Concanavalin-A - Sepharose Chromatography. Con- 
canavalin- - Sepharose was packed in a column (2.2 cm 
x 17.5 cm) and equilibrated with 20 mM potassium phosphate 
buffer pH 7.0. The dialysed (NH4),S04 suspension was passed 
through the column and the column washed with 300 ml of 
equilibration buffer containing 0.5 M NaCl. The enzyme was 
eluted at  25 "C with the equilibration buffer containing 0.5 M 
methyl a-glucoside and 0.5 M NaCl. The active fractions 
(fraction numbers 1 - 9) of 5 ml each were pooled and dialysed 
against 3 1 of equilibration buffer. 
Step 4 .  Sepharose 6 B  Gel Filtration. The dialysed con- 
canavalin-A - Sepharose eluate was concentrated by lyophili- 
zation, dialysed against 20 mM potassium phosphate buffer 
pH 7.0 containing 0.15 M NaCl and applied on a Sepharose 6B 
column (2.2 cm x 47 cm) previously equilibrated with the same 
buffer. The enzyme was eluted by the same buffer at a flow rate 
of 15 ml/h and fractions of 5 ml were collected. Active fractions 
(fractions 14- 20) were pooled. 
The purified liver enzyme was free of any detectable 
monoamine oxidase activity. 
Inhibition or Activation Studies 
The purified enzymes were dialysed against 20mM po- 
tassium phosphate buffer pH 7.0 and used for the above 
studies. The inhibitors or activators were added to the assay 
blanks to avoid any interference by them. Cholinesterase 
inhibition studies were performed by preincubating the en- 
zymes with the inhibitor for 10 min at  37 "C before assay. 
Gel Electrophoresih 
Polyacrylamide gel electrophoresis was done according to 
the method of Davis [25]. The samples concentrated by 
aquacide about tenfold and dialysed against 0.05 M Tris/HCl 
buffer pH 7.0 were subjected to electrophoresis at 4 "C on 7 % 
gels at 3 mA per tube in 0.05 M Tris/glycine buffer pH 8.0 till 
the tracking dye bromophenol blue emerged. The gels were 
fixed in 12.5 trichloroacetic acid and stained with 0.05 % 
Coomassie brilliant blue. For estimating the enzyme activities 
in the gel, the gels were sliced to 1.5-mm thickness, the enzyme 
extracted into 0.5 ml 20 mM potassium phosphate buffer 
pH 7.0 containing 0.5 "/, Triton X-100 for 48 h and the activity 
in the extract was estimated. 
Sodium Dodecyl Suljate Gel Electrophoresis 
The method of Laemmli [26] in a Tris/glycine system was 
employed for sodium dodecyl sulfate gel electrophoresis. The 
gels were cast in 0.1 % sodium dodecyl sulfate. Samples were 
boiled for 2 min in 2 "/, sodium dodecyl sulfate containing 5 "/, 
2-mercaptoethanol and 20 pg of sample protein was applied on 
gel. Electrophoresis was carried out at a constant current of 
3 mA per tube at room temperature. Proteins were stained as 
described by Laemmli [26]. 
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Preparation of Antibody 
Step 1. Antibody against serum aryl acylamidase was raised 
by injecting intradermally into a young rabbit 300 pg of 
purified aryl acylamidase in 1 ml water mixed with 1 ml of 
Freund’s complete adjuvant. Booster doses of 200 pg and 
150 pg of the purified enzyme were injected on the 22nd and 
25th day respectively. A week later the rabbit was bled through 
the marginal vein of the ear. 
Step 2. ( N H 4 j z S 0 4  Precipitation. The clotted blood was 
centrifuged and the serum collected. The serum was saturated 
with (NH4),S04 to 52 % and the precipitated proteins centri- 
fuged down at 12000 x g for 30 min. The pellet was suspended 
in 20 mM potassium phosphate buffer pH 6.8 and dialysed 
against 3 1 of the same buffer. 
Step 3. DEAE-cellulose Chromatography. Precycled DEAE- 
cellulose (DE32) was packed in a column (1.8 cm x 18.5 cm) 
and equilibrated with 20 mM potassium phosphate buffer 
pH6.8 and the (NH4)2S0, suspension was applied to the 
column. The column was washed with the same buffer and the 
washings were collected and dialysed against water and lyophi- 
lized. 5 mg lyophilized antibody was dissolved in 1 ml of 
phosphate-buffered saline p H  7.0. The purified antibody was 
free of any detectable aryl acylamidase or cholinesterase 
activities. 
Immunodiffusion Studies 
Double immunodiffusion experiments were done on 1 % 
agarose gel made in phosphate-buffered saline pH 7.0 contain- 
ing 0.02 % sodium azide as described by Ouchterlony [27]. 
Immunoprecipitation Studies 
To 0.15 ml of the purified serum, erythrocyte or liver 
enzyme preparations, 0.15 ml ofthe reconstituted antibody was 
added and kept at 4 “C for 48 h and centrifuged at 3500 x g for 
30 min. The supernatant was separated and estimated for both 
aryl acylamidase and cholinesterase activities. Controls consis- 
ted of 0.15 ml of each enzyme and 0.15 ml of phosphate- 
buffered saline pH 7.0. 
Enzyme Assuys 
Aryl acylamidase was assayed as described earlier [19]. 
Serum aryl acylamidase was assayed at pH 8.0, erythrocyte at  
pH 7.0 and liver at p H  6.5 based on their pH optima profile. 
Cholinesterase was assayed according to Ellman et al. [28] as 
described earlier [18]. Cholinesterase activities of all the three 
sources were estimated at pH 8.0. Serum cholinesterase was 
assayed using butyrylthiocholine as substrate, erythrocyte 
cholinesterase using acetylthiocholine and liver cholinesterase 
using both acetyl thiocholine and butyrylthiocholine as sub- 
strates. 1 unit of aryl acylamidase corresponds to 1 pmole 
o-nitroacetanilide hydrolysed/h and 1 unit of cholinesterase to 
a change in absorbance of l/min at  412 nm under standard 
assay conditions. Monoamine oxidase was assayed according 
to the method of Green and Haughton [29] with tyramine 
hydrochloride as substrate. 
Protein Estimations 
Protein concentration were determined according to the 
method of Lowry et al. [30] using crystalline bovine serum 
albumin as standard. Protein in column fractions was moni- 
tored by measuring absorbance at 280 nm. 
All purification procedure were carried out at 4 -C unless 
otherwise mentioned. 
RESULTS 
Put-ifreat ion of Human Serum Arvl Acylamiduse 
Fresh serum aryl acylamidase and cholinesterase were 
completely bound to the DEAE-cellulose, but with aged serum 
samples a small amount (about 12 %) of both aryl acylamidase 
and cholinesterase activities did not bind to the DEAE- 
cellulose. The binding of the enzyme to concanava1in-A- 
Sepharose was minimal at  pH 7.0 and complete at  pH 5.0. A 
ten-carbon spacer arm was found superior to a six-carbon 
spacer arm for binding the enzyme to the procainamide- 
Sepharose column. Table 1 summarises the schenie of a typical 
purification of serum aryl acylamidase and cholinesterase. A 
final purification of 13 850-fold was achieved for aryl acyl- 
amidase and 13 620-fold for cholinesterase with about 44 % 
recovery for both the enzymes. 
In all the steps of purification, both aryl acylamidase and 
cholinesterase activities co-purified with the same ratio of 
activities and percentage recoveries (Table 1). The elution 
profiles in all the column chromatographic procedures were 
also identical for the two enzymes (Fig. 1). 
Table 1. Purification of human serum aryl ucylamiduse and cholinesterase 
Enzyme units are defined in Materials and Methods. AAA = aryl acylamidase; ChE = serum cholinesterase 
Purification Vol- Total activity Protein Specific activity Ratio of Purification Recovery 
step ume - ~. ~ - ~ 
AAA ChE AAA ChE ChE/AAA AAA ChE AAA ChE 
mi units mg units/mg protein -fold x 
~ __ - ~~ ~ - ~ .~ 
~ Plasma 200 100 15200 15800 0.00632 0.962 152 - 100 100 
Serum pH 4.0 214 83.5 12550 7810 0.0071 1.607 150.4 1.17 1.11 83.4 82.6 
DE AE-ceitulose 275 64.3 9 590 15.3 4.196 627 1 49 664 652 64.3 63.1 
Concanavalin-A - 20 52.8 7 790 3.5 15.12 2223 147.3 2400 2312 52.7 51.2 
Sepharose 
Procainamide affinity 
chromatography 52 43.9 6760 0.52 84.4 13000 154 13850 13620 43.9 44.4 
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Fig. 1. Elution profiles of serum aryl acylumidase and cholinesterase. 
Chromatographic procedures are described under Materials and Methods. 
(A) DEAE-cellulose chromatography, (B) concanavalin-A - Sepharose 
chromatography and (C) procainamide-Sepharose affinity chromatog- 
raphy. The arrow indicates commencement of elution with NaCl gradient. 
(0-1 Aryl acylamidase; (0 --0) cholinesterase; (A-A) absorbance at 
280 nm 
o 5 10 60 65 70 75 ao 
Purification of Erythrocyte Aryl Acylarnidase 
Details of the purification are given elsewhere [19]. Several 
lines of evidence indicating the identity of the erythrocyte 
membrane aryl acylamidase with acetylcholinesterase has been 
reported by us earlier [19]. 
Purijkation of Human Liver Aryl Acylumidase 
Table 2 summarises the purification of human liver aryl 
acylamidase and cholinesterase. The latter activity was mea- 
sured using both acetylthiocholine and butyrylthiocholine as 
substrates. Although in the crude homogenate the cholines- 
terase activity measured using acetylthiocholine was slightly 
higher than that with butyrylthiocholine, in the final prepara- 
tion the activity with butyrylthiocholine was double that 
obtained with acetylthiocholine. This may be due to the 
progressive removal of the acetylcholinesterase component of 
the liver [31] during the initial steps of purification. In the final 
step of purification the aryl acylamidase was purified about 43- 
fold with 35 % recovery while the cholinesterase activity was 
purified only about 5 - 1 I-fold with a recovery of 4- 9 % 
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Fig. 2. Elution profiles of liver aryl acylamidase and cholinesterase. 
Experimental details are given under Materials and Methods. (A) 
Concanavalin-A - Sepharose chromatography; (B) Sepharose 6B gel 
filtration. The arrow indicates the void volume. (o-) Aryl acylamidase; 
(m-) cholinesterase activity with butyrylthiocholine as substrate; 
(0 - a) cholinesterase activity with acetylthiocholine as substrate 
(Table 2). The ratio of cholinesterase to aryl acylamidase varied 
from 2.77-1.56in theinitialstep to0.2-0.39in the finalstep. 
Although both cholinesterase and aryl acylamidase activities of 
liver showed a similar pattern of elution in the concanavalin- 
A - Sepharose chromatography (Fig. 2A) their elution pattern 
on Sepharose 6B showed a clear difference (Fig. 2B). 
Alternative Chromatographic Methods Tried ,for Liver 
and Serum Enzymes 
Attempts were made to purify the liver aryl acylamidase by 
methods similar to those used for the serum enzyme. DEAE- 
cellulose chromatography was not suitable because although 
the liver aryl acylamidase from the 55 000 x g supernatant 
bound to the column at pH 7.0, no significant activity could be 
eluted with NaCl alone in the buffer. When 0.1 % (v/v) Triton 
X-100 was included in the eluting buffer, aryl acylamidase 
activity was eluted but it was distributed in a large number of 
fractions. 
Procainamide-Sepharose affinity chromatography was 
tried for the liver aryl acylamidase using either the fraction 
obtained after concanavalin-A - Sepharose chromatography 
or the 55000 x g supernatant. With the former it was found that 
about 99% of the aryl acylamidase along with the major 
protein content came out without binding to the column and 
almost all the cholinesterase activity (using both acetyl- 
thiocholine and butyrylthiocholine as substrate) in the frac- 
tions eluted from the affinity column. Although the 
Table 2. Purififatioiz of aryl acylamidase from human liver 
Enzyme units are defined in Materials and Methods. AAA = aryl acylamidase; AChE = Cholinesterase activity using acetylthiocholine as substrate; 
BuChE = cholinesterase using butyryl thiocholine as substrate 
Purifi- Vol- Total activity Pro- Specific activity Ratio of activities Purification Recovery 
cation ume tein 
step - 
AAA AChE BuChE AAA AChE BuChE AChE/ BuChE/ AAA AChE BuChE AAA AChE BuChE 
AAA AAA 
ml units mg units/mg protein -fold % 
Homo- 
1.77 1.56 - - -  100 100 100 genate 84 58.2 102.8 90.8 907 0.064 0.113 0.1 
55000 x g  
Super- 
natant 78 39 58.7 57.2 749 0.052 0.078 0.076 1.51 1.47 ~ - - 67 63 57 
(NH,),SO, 
precipi- 
tation 41 30.7 17.6 23.1 318 0.097 0.055 0.072 0.57 0.75 1.5 0.49 0.72 53 17 25 
Concana- 
valin-A - 
Sepharose 44 24 8.9 15.7 21 1.13 0.42 0.74 0.37 0.65 17.7 3.7 7.4 45 8.6 17 
tration 30 20.6 4.16 8.0 7.4 2.78 0.56 1.08 0.2 0.39 43.4 5.0 10.8 35 4 8.8 
Gel fil- 
procainamide-Sepharose chromatography could not be used 
for purifying the liver aryl acylamidase, it gave a clear-cut 
separation of the liver aryl acylamidase from liver cholines- 
terase indicating the non-identity of the two enzymes. When the 
55000 x g supernatant was used, a similar profile was obtained 
except about 15 % of cholinesterase activity (using acetyl- 
thiocholine but not butyrylthiocholine as substrate) was detect- 
able in the fractions not bound to the column. This may 
represent a small amount of acetylcholinesterase present in the 
crude 55000 x g supernatant of the liver [31]. 
Crude serum after subjecting to a procainamide-Sepharose 
chromatography (where almost 99 % of both aryl acylamidase 
and cholinesterase activity was bound to the column and 
recovered in elution) was applied on a Sepharose 6B column of 
dimensions Similar to that used for the purification of liver aryl 
acylamidase (see Fig.2B). It was found that both aryl acyl- 
amidase and cholinesterase activities co-eluted and the activity 
was distributed over fractions 10- 15 with a single sharp peak 
of activity in fraction 12 (see Fig. 2B). This indicated a higher 
molecular weight for the serum aryl acylamidase compared to 
the liver aryl acylamidase. 
Polyacrylamide Gel Ebctrophoresih 
Purified serum aryl acylamidase showed a single protein 
band on polyacrylamide gel electrophoresis (Fig. 3A). The 
same enzyme on sodium dodecyl sulfate gel electrophoresis 
showed a single protein band (Fig. 3B) and its molecular weight 
as calculated from marker proteins (immunoglobulin G, bo- 
vine serum albumin, ovalbumin and trypsin inhibitor) was 
68 000. 
Both the aryl acylamidase and cholinesterase activities of 
serum co-migrated on polyacrylamide gel electrophoresis un- 
der non-denaturing conditions and corresponded to the single 
protein band (Fig.4A). The purified liver enzyme upon gel 
electrophoresis showed differences in the migration pattern of 
aryl acylamidase and cholinesterase activities (Fig. 4B). While 
Fig. 3. ( A )  Polyacrylamide gel electrophoresis of the purified serum aryl 
acylamidase; (3) sodium dodecyl sulfate gel electroplzoresis of the purified 
serum arylae.ylamidase. Migration was from top to bottom towards anode. 
Details are given under Materials and Methods 
all the cholinesterase and a part of the aryl acylamidase 
activities were located in the first two gel slices (stacking gel), a 
major portion of the aryl acylamidase activity was found in gel 
slices 14 - 20 without any cholinesterase activity. When elec- 
trophoresis of the purified liver enzyme was done on a 4 %  
polyacrylamide gel (figure not given) instead of a 7 %  gel, a 
similar profile was seen. However a sample of the same enzyme 
without concentration by aquacide when subjected to elec- 
trophoresis on a 4 %  gel did not show any detectable aryl 
acylamidase activity in the first two gel slices but showed 
enhanced activity in gel slices 13 - 16 (see Fig. 4B). It is possible 
that on concentration a part of the purified liver aryl acyl- 
amidase migh have aggregated into a form that could not enter 
the separating gel. It should be noted that all the cholinesterase 
A 
1 5  10 15 20 3 0  
S l i c e  n u m b e r  
Fig. 4. Profiles of enzyme activity in the gel slices after polyacrylumide gel 
electrophoresis. (A) Purified serum aryl acylamidase ( 0 4 )  and cholines- 
terase (o--o); (B) purified liver aryl acylamidase (0-) and cholines- 
terase with butyrylthiocholine as substrate (0 --0) and acetylthiocholine 
as substrate (A-A). Gel slices 1 and 2 include the stacking gel 
activity of both concentrated and dilute samples of the liver 
enzyme remained in the first two gel slices. Polyacrylamide gel 
electrophoresis of the erythrocyte enzyme showed co-migration 
of both aryl acylamidase and acetylcholinesterase activities as 
reported earlier [19]. 
The crude serum and liver enzymes were also subjected to 
electrophoresis on 4 % polyacrylamide gels. Crude serum after 
being subjected to a procainamide-Sepharose chromatography 
(with 99% recovery of both aryl acylamidase and cholines- 
terase activities) showed on electrophoresis co-migration of 
both the activities. The activity profile was similar to that 
observed with the purified enzyme (see Fig. 4A) except that it 
was detectable in about six gel slices, slices 3 - 8, with a single 
sharp peak on slice 7. A 55000 x g supernatant of liver on 
electrophoresis also gave a profile similar to that obtained with 
the purified liver enzyme. Almost 98 % of aryl acylamidase was 
located as a peak in the separating gel and about 2 %  was 
present in the stacking gel. All the liver cholinesterase activity 
was located in the stacking gel. 
Effect of Amines and Choline Derivatives 
on the Aryl Acylamidases 
We had reported earlier [I91 that acetylcholinesterase from 
brain, erythrocytes and electric eel have an aryl acylamidase 
activity which is inhibited specifically by the amine serotonin as 
well as by acetylcholine, its analogues and homologues. 
Tables 3 and 4 show the effect of different amines, their 
derivatives and choline derivatives on the purified aryl acyl- 
arnidases from serum, erythrocytes and liver. Among the 
amines, serotonin followed by tryptamine was the strongest 
inhibitor of erythrocyte aryl acylamidase. The serum aryl 
acylamidase was also inhibited by serotonin to a lesser extent 
Table 3. Inhibition ofpurified aryl acylamidases of serum, erythrocytes and 
liver by amines and their derivatives 
n.s. = not significant (either 0% or < 1 % inhibition) 
Inhibitor Concn Inhibition of aryl 
acylamidase from 
serum erythrocyte liver 
~ - -~  ~ ~~~ ~~ 
mM % 
~ ~~~ ~ 
Serotonin 10 60 96 n. s. 
5 55 93 n.s. 
1 40 86 n.s. 
0.1 16 54 n.s. 
Tryptamine 10 82 74 n.s. 
5 78 65 n.s. 
1 67 36 n.s. 
0.1 25 6 n.s. 
Dopamine 10 29 18 n.s. 
1 18 8 n. s. 
0.1 5 n.s. n.s. 
5-Methoxy tryptamine 10 47 8 n.s. 
1 18 4 n.s. 
0.1 2 2 n. s. 
Benzylamine 10 9 28 n.s. 
1 n.s. 10 n.s. 
0.1 n.s. n.s. n.s. 
Kynuramine 1 23 55 n. s. 
0.1 n.s. 10 n. s. 
Indole-3-propionic acid 2 31 3 48 
1 18 2 41 
0.1 2 n.s. I 
Indole-3-acetic acid 0.5 13 5 14 
0.1 5 3 8 
acetic acid 1 n. s. n. s. 5 
5-Hydroxyindole 
Table 4. Inhibition ofpurified serum, erythrocyte and liver uryl acylamidase 
by choline derivatives 
n.s. = not significant (either 0 % or less than 1 inhibition) 
Inhibitor Concn Inhibition 
of aryl acylamidase from 
serum erythrocyte liver 
mM "/, 
Acetylcholine 10 73 
- 
1 44 
Propionylcholine 10 67 
1 25 
Butyrylcholine 10 56 
1 12 
Succinylcholine 10 97 
1 78 
Benzoylcholine 10 70 
1 29 
Acetyl-j- methylcholine 10 66 
1 32 
Choline 10 61 
1 19 
~~ 
87 
28 
84 
25 
91 
60 
73 
40 
90 
56 
70 
21 
71 
24 
~ 
n. s. 
n. s 
5 
n. s. 
n.s. 
n.s. 
3 
n.s. 
n. s. 
n. s. 
n.s. 
n.s. 
n. s. 
n. s. 
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and by tryptamine to a greater extent. The only other amine 
which gave a significant inhibition of both erythrocyte and 
serum aryl acylamidase was kyneuramine. 5-Methoxy- 
tryptamine, dopamine and benzylamine were much less in- 
hibitory (Table 3). Other amines like norepinephrine, his- 
tamine and tyramine were poor inhibitors of the erythrocyte 
and serum aryl acylamidase. Tyramine was an activator of 
serum aryl acylamidase (see below). Amino acids like tryp- 
tophan, 5-methoxy-tryptopha11, tyrosine and 4-aminobutyric 
acid had no effect up to 5 mM on the serum or erythrocyte aryl 
acylamidase. The liver aryl acylamidase was unaffected by 
all the above-mentioned compounds. However indole-3- 
propionic acid and indole-3-acetic acid inhibited the liver aryl 
acylamidase and to a lesser extent the serum aryl acylamidase 
+800 1 
I 
> 
c - 
:: t400 
m 
c 
a, 
ISI c 
.- 
," +zoo 
0 
0 
-100 .. 
0 0.5 1.0 5 10 
Tyramine (mM) 
Fig. 5 .  Effect of tyraniine at various concentrations on the purified ary1 
acylamidase f iom serum ( 0 4 ) ,  erythrocyte (O-) and liver (A-A) 
lo-$ 1 0 . ~  10+ 
Neost igmine (M) 
with no significant effect on the erythrocyte enzyme (Table 3). 
These findings on liver aryl acylamidase were similar to our 
earlier observations [21]. Acetylcholine and other choliiie de- 
rivatives were inhibitory to both the erythrocyte and serum aryl 
acylamidase (Table 4). Succinylcholine and butyrylcholine 
were the most efficient inhibitors of serum and erythrocyte 
aryl acylamidase respectively. None of the choline derivatives 
had any significant effect o n  the liver aryl acylamidase. 
Serotonin was a non-competitive inhibitor of aryl acyl- 
amidase of serum and erythrocyte and the Ki values from 
Dixon plots were 4.5 mM and 0.125 mM respectively. 
Activation of Serum Aryl Acylumidase by Tyrumine 
An interesting observation made was the activation of 
serum aryl acylamidase by tyramine (Fig. 5). There was a 4-fold 
activation at  1 mM and 6.5-fold activation at 5 mM tyramine. 
Neither the erythrocyte aryl acylamidase nor liver aryl acyl- 
amidase was significantly affected by tyramine up to 10 mM 
(Fig.5). The activation of the serum aryl acylamidase was 
shown specifically by tyramine (4-hydroxyphenethylamine) 
and not by its structural analogues (3,4-dihydroxy- 
phenyl)alanine(dopa) and 3,4-dihydroxyphenethylamine (do- 
pamine). Tyramine (up to 5 mM) did not show any activation 
of the serum or liver cholinesterase. The ability of tyramine to 
activate the serum aryl acylamidase was also tested at different 
pH between pH 6 and 9 using 0.5 mM tyramine. About 3 -4- 
fold activation was found at all p H  between 6 and 8 and about 
7-fold activation at pH9. The erythrocyte and liver aryl 
acylamidases were not activated at  any of these pH values by 
tyramine. 
Inhibition by Eserine, Neostigmine 
and Selective Cholinesterase inhibitors 
Eserine and neostigmine, potent inhibitors of cholines- 
terase, inhibited the aryl acylamidase as well as cholinesterase 
activities of both serum and erythrocytes. At I pM eserine and 
B 
1 0 . ~  10-7 1 0 . ~  
lo-$ 1 0 . ~  1 0 . ~  
Neost igmine (M) 
1 Eserine (M) 
10-9 10-7 
lo-$ 1 0 . ~  
Neostigmine (M) 
Fig. 6 .  Inhibition by eserine and neostigmine ofpurified aryl acylamidase and cholinesterase from erythrocyte, serum andliver. (A, B, C )  Inhibition patterns of 
the erythrocyte, serum and liver enzymes respectively by eserine; (D, E, F) inhibition patterns of the respective enzymes by neostigmine. ( 0 4 )  Aryl 
acylamidase; (A-A) cholinesterase with butyrylthiocholine as substrate; (0 ~~ 0) cholinesterase with acetylthiocholine as substrate 
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Fig. I. Inhibition ofpurified erythrocyte, serum and liver aryl acylamidase and cholinesterase by tetraisopropylpyrophosphoramide and B W284C51. (A, B, C) 
Inhibition patterns of erythrocyte, serum and liver enzymes by tetraisopropylpyrophosphoramide; (D, E, F) inhibition patterns of the respective enzymes 
by BW284C51. (.+) Aryl acylamidase; (A-A) cholinesterase using butyrylthiocholine as substrate; (O--O) cholinesterase using acetylthiocholine as 
substrate 
10 pM neostigmine inhibition was nearly 100% of both the 
enzyme activities from both the sources (Fig. 6). However the 
liver aryl acylamidase was unaffected by either eserine or 
neostigmine up to 100 pM while the liver cholinesterase was 
completely inhibited at  100 pM (Fig. 6). 
The ratio of cholinesterase activities (butyrylthiocholine to 
acetylthiocholine as substrate at equimolar concentrations) 
was 0.037,1.96 and 2.14 for the purified erythrocyte, serum and 
liver enzymes. In order to classify the cholinesterases from the 
different sources a selective inhibitor of acetylcholinesterase, 
viz BW284C51 [ 5 ] ,  and a selective inhibitor ofpseudocholines- 
terase, viz. tetraisopropylpyrophosphoramide [6], were em- 
ployed for inhibition studies of the arylacylamidases and 
cholinesterases from erythrocytes, serum and liver (Fig. 7). 
BW284C51 inhibited erythrocyte aryl acylamidase and acetyl- 
cholinesterase more than 90 % at 10 pM concentration while 
tetraisopropylpyrophosphoramide inhibited both the enzymes 
only less than 10 % at the same concentration. Conversely aryl 
acylamidase and cholinesterase of serum were inhibited more 
than 80 % at 10 pM tetraisopropylpyrophosphoramide and 
only less than 30 % by BW284C51 at the same concentration. 
Liver aryl acylamidase and cholinesterase were not signif- 
icantly inhibited by BW284C51 at I0 pM while tetraisopro- 
pylpyrophosphoramide at 10 pM inhibited the enzymes to 
varying extent. At high concentrations of the inhibitors the 
extent of inhibition of the aryl acylamidase, acetylcholines- 
terase and butyrylcholinesterase activities of the liver enzyme 
varied widely. The liver cholinesterase exhibited more in- 
hibition by tetraisopropylpyrophosphoramide when butyryl- 
thiocholine was the substrate and by BW284C51 when acetyl- 
thiocholine was the substrate. 
Immunologicul Studies 
Purified antibody raised against serum aryl acylamidase 
showed cross-reactivity with the serum aryl acylamidase but 
not erythrocyte aryl acylamidase on double immunodiffusion 
in 1 % agarose gel (Fig. 8). It gave precipitin lines with purified 
liver aryl acylamidase. However the serum precipitin lines and 
the liver precipitin lines did not fuse but crossed at the ends to 
reveal their immunological non-identity. In order to find out 
whether the precipitin lines formed in the double immunodif- 
fusion were due to the enzyme proteins themselves, the 
precipitin lines were cut out from the gel after thorough 
washing of the gel and tested for the enzyme activities. Whereas 
the precipitin line formed between the antibody and the serum 
enzyme showed remarkable aryl acylamidase and cholines- 
terase activities, the precipitin line formed by the liver enzyme 
did not show any activity at all. This led us to conclude that the 
precipitin line formed by the liver enzyme must have been due 
to a non-specific protein other than the aryl acylamidase or 
cholinesterase. This conclusion is also in accord with our 
inability to immunoprecipitate the liver enzyme activities by the 
antibody as described below. 
Immunoprecipitation of the enzyme activities by the anti- 
body could be achieved only with the serum enzyme. Both aryl 
acylamidase and cholinesterase activities of serum could be 
precipitated and sedimented by centrifugation (Fig. 9). The 
ratio of aryl acylamidase to cholinesterase activity precipitated 
at different dilutions of the antibody was constant. Liver and 
erythrocyte enzymes could not be sedimented even with high 
concentrations of antibody. An attempt made to precipitate 
any complex formed between the antibody and the liver or 
185 
Fig. 8. Douhle immuriodflusiun pattern of the antibody raised against 
purijiedseruni aryl ucylainidase and the purifierlserum, liver anderythrocyte 
enzymes. Center well contained 15 p1 of reconstituted antibody (see 
Materials and Methods). Wells 2 , 4  and 5 contained 15 p1 of purified serum 
enzyme and wells 1 and 3 contained 15 pl of purified erythrocyte and liver 
enzymes respectively. The precipitin line formed by the serum enzyme 
showed remarkable aryl acylamidase and cholinesterase activities, but the 
precipitin line formed by the liver enzyme had no activity 
1:16 1:8 1:4 1'2 1 : l  0 
Di lu t i on  o f  a n t i b o d y  
Fig. 9. Immunoprecipitation of the purified serum, liver and erythrocyte 
enzymes by  antibody raised against purified serum enzyme. 0.15 ml of the 
reconstituted antibody (see Materials and Methods) at different dilutions 
was mixed with 0.15 ml of each of the enzymes and incubated at 4 C for 
24 h, centrifuged and the supernatant assayed for enzyme activities. The 
results are expressed as a percentage of original activity in the absence of 
antibody in the supernatant after centrifugation. (0+) Serum aryl 
acylamidase; (O-) serum cholinesterase; (m-) erythrocyte aryl acyl- 
amidase; ( 0 4 )  erythrocyte cholinesterase; (A-A) liver aryl acyl- 
amidase; (A-A) liver cholinesterase assayed using butyrylthiocholine and 
acetylthiocholine as substrate 
Table 5. The comparative characteristics of puri jkd  uryl acylamidases from hunian erythrocytes, serum and liver 
Property Source of aryl acyldinidase 
erythrocyte serum 
-~ ~~~~ ~ ~ ~ - ~ - 
1. 
2. 
3.  
4. 
5. 
Relationship to cholinesterase 
Arnine sensitivity 
Sensitivity to choline 
deritatives 
Sensitivity to cholinesterase 
inhibitors 
Immunological characteristics 
associated with erythrocyte 
acetylcholinesterase 
inhibited by serotonin and 
tryptamine; not affected by 
tyramine 
inhibited by butyrylcholine and 
other choline derivatives 
inhibited by eserine, neostigmine 
and selectively by BW2X4C51 
immunologically different 
from serum enzyme 
associated with serum 
pseudocholinesterase 
inhibited by tryptamine and 
serotonin; tyramine significantly 
activates 
inhibited by succinylcholine and 
other choline derivatives 
inhibited by eserine, neostigmine 
and selectively by tetraisopropyl- 
pyrophosphoramide 
immunologically different 
from erythrocyte and liver 
enzymes 
not associated with liver cholines- 
terase activity 
unaffected by serotonin, tryptarnine 
and tyramine 
unaffected by any of the choline 
derivatives tested 
not inhibited by eserine and neostig- 
mine; tetraisopropylpyrophosphor- 
amide inhibits a t  relatively high 
concentration 
immunologically different from 
serum enzyme 
erythrocyte enzymes by forming a tertiary complex with anti- 
(rabbit IgG) also proved futile. 
DISCUSSION 
In our earlicr studies [I91 we have provided several lines of 
evidence for the identity of the serotonin-sensitive aryl acyl- 
amidase with acetylcholinesterase from three different sources, 
viz. sheep basal ganglia, human erythrocytes and electric eel. In 
the present work we show the identity of the human serum aryl 
acylamidase (purified to homogeneity) with the serum cholines- 
terase on the basis of the following evidence: (a) their co-elution 
in all the column chromatographic procedures including af- 
finity chromatography, (b) their co-purification in all the steps 
with constant ratios of activity and percentage recoveries, (c) 
their co-migration in gel electrophoresis, (d) their parallel 
inhibition by typical cholinesterase inhibitors and (e) their co- 
precipitation by antibody raised against the purified enzyme. 
The inhibition characteristics, particularly with tetraisopropyl- 
pyrophosphoramide, a selective inhibitor of pseudocholines- 
terase, and with BW284C51, aselective inhibitor of acetylcho- 
linesterase, clearly differentiated between the erythrocyte and 
serum aryl acylamidase on the one hand and also confirmed 
their identity with the respective cholinesterases on the other. 
The amine sensitivity studies indicate that the erythrocyte aryl 
acylamidase shows a higher sensitivity to serotonin inhibition 
as compared to the serum aryl acylamidase. Both enzymes were 
inhibited to varying extent by choline derivatives. A more 
significant observation was the activation by tyramine of serum 
aryl acylamidase but not erythrocyte aryl acylamidase. 
The human liver aryl acylamidase appears to be an entirely 
different type of enzyme as compared to the erythrocyte and 
serum aryl acylamidases. The liver enzyme was not sensitive to 
inhibition by any of the amines or choline derivatives, it was not 
activated by tyramine and it was not inhibited by the typical 
cholinesterase inhibitors like eserine and neostigmine. 
Furthermore the liver aryl acylamidase did not appear to be 
associated with the liver cholinesterase as evidenced by the 
purification data (Table 2), their clear-cut separation on 
procainamide-Sepharose, elution profiles on Sepharose 6B 
(Fig. 2B), inhibition characteristics by eserine and neostigmine 
(Fig. 6) and the electrophoretic migration on polyacrylamide 
gel (Fig. 4B). Immunodiffusion and immunoprecipitation 
studies showed that aryl acylamidase from serum is different 
from those present in erythrocyte and liver. The comparative 
characteristics of the aryl acylamidases from the three sources 
are summarised in Table 5. 
Although the evidence for the association of aryl acyl- 
amidase with cholinesterase has been mostly sought in the 
purified enzyme preparations of serum and liver, some experi- 
ments were also done on the crude enzymes. For example 
procainamide-Sepharose chromatography of crude liver en- 
zyme (55 000 x g supernatant) gave a clear-cut separation of the 
aryl acylamidase and cholinesterase activities indicating their 
non-association. Gel electrophoresis of the crude liver enzyme 
also indicated a clear separation of almost 98% of the aryl 
acylamidase activity from cholinesterase. Crude serum on 
procainamide-Sepharose chromatography showed co-elution 
of both aryl acylamidase and cholinesterase activity in 99 % 
yield. This preparation on gel electrophoresis also showed co- 
migration of both the activities as found with the purified 
serum enzyme. Moreover Sepharose 6B gel filtration of this 
preparation resulted in the co-elution of both enzyme activities. 
These studies make it highly unlikely that any major form of 
aryl acylamidase not associated with cholinesterase activity in 
the serum or associated with cholinesterase activity in the liver 
might have been lost or gone undetected during the purification 
procedures. At least the separation techniques employed in the 
present studies indicate that such a possibility is remote. 
The present studies indicate similarities between the 
serum and liver cholinesterases in their affinity towards 
procainamide-Sepharose, their inhibition characteristics by 
typical cholinesterase inhibitors and their specificity towards 
butyrylthiocholine as substrate. The apparent differences be- 
tween the cholinesterases of the two sources are that the liver 
cholinesterase unlike the serum enzyme is not associated with 
aryl acylamidase, is immunologically non-identical with the 
serum cholinesterase and also differs from the serum cholines- 
terase in its electrophoretic mobility on polyacrylamide gel and 
elution profile on Sepharose 6B gel filtration. 
It is likely that only those aryl acylamidase which are 
associated with cholinesterases (like those found in eryth- 
rocytes, serum, basal ganglia or electric eel) show sensitivity 
towards the amines serotonin or tryptamine and choline 
derivatives. Moreover tyramine activation appears to be a 
characteristic property of the aryl acylamidase associated with 
the serum type of cholinesterase. These characteristics of aryl 
acylamidase and those summarised in Table 5 may prove to be 
useful indexes of the type of cholinesterases present in the tissue 
or body fluids. These studies also indicate that the aryl 
acylamidases and cholinesterases from the three sources have 
major differences in their properties suggesting that they may 
be products of different genes. 
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